Lawrence Shulman, MD
Pulmonary Disease · Lake Success, NYNPI 1265471585
Payments from drug & device makers
Across 592 payments — averaging $384.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$212K
- Pfizer$7K
- Viiv Healthcare Company$2K
- Sanofi Pasteur Inc.$1K
- Boehringer Ingelheim$825
- AstraZeneca$466
- plus $4K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 297 | $212,425 |
| Pfizer | 27 | $6,794 |
| Viiv Healthcare Company | 1 | $1,600 |
| Sanofi Pasteur Inc. | 1 | $1,488 |
| Boehringer Ingelheim | 37 | $825 |
| AstraZeneca | 21 | $466 |
| Mylan Specialty L.p. | 21 | $399 |
| Sunovion Pharmaceuticals Inc. | 19 | $375 |
| Actelion Pharmaceuticals US, Inc. | 13 | $364 |
| Genentech USA, Inc. | 19 | $307 |
| Philips North America LLC | 15 | $289 |
| Globus Medical | 1 | $256 |
| Electromed, Inc. | 15 | $231 |
| Jazz Pharmaceuticals Inc. | 10 | $221 |
| Harmony Biosciences LLC | 9 | $207 |
| Sanofi | 8 | $185 |
| Advanced Respiratory, Inc | 10 | $182 |
| Regeneron Healthcare Solutions, Inc. | 8 | $175 |
| Grifols USA, LLC | 10 | $170 |
| Merck | 9 | $169 |
| Eisai Inc. | 9 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $128 |
| Circassia Inc. | 4 | $74 |
| Gilead | 3 | $61 |
| Shire North American Group Inc | 3 | $45 |
| Amgen | 2 | $38 |
| Apria Healthcare LLC | 2 | $34 |
| Insmed, Inc. | 2 | $25 |
| Viatris Specialty LLC | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Bayer | 1 | $24 |
| Novartis | 2 | $23 |
| AbbVie | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $14 |
How this compares
$227,893 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lake Success
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.